U.S. Supreme Court Decision Narrows Roundup Litigation Path, Spotlighting Design Defect Claims

The landscape of litigation surrounding Monsanto’s herbicide, Roundup, has undergone significant shifts following recent judicial decisions. Central to these developments is the U.S. Supreme Court’s ruling in Monsanto Co. v. Durnell, which has redefined the parameters of legal claims against the company.

On June 25, 2026, the Supreme Court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims that would necessitate a cancer warning on Roundup’s label. This decision effectively bars plaintiffs from pursuing claims based on the assertion that Monsanto failed to provide adequate warnings about the product’s carcinogenic risks. However, the Court did not address other legal theories, leaving the door open for claims such as design defect and negligence. ([mdlupdate.com](https://mdlupdate.com/mdl/2741-roundup/?utm_source=openai))

In the wake of the Durnell decision, attention has turned to the viability of design defect claims. U.S. District Judge Vince Chhabria, overseeing the multidistrict litigation (MDL) in the Northern District of California, has solicited amicus briefs to determine whether FIFRA preempts design defect and negligence claims under the laws of several states, including Florida, Ohio, North Carolina, Mississippi, Georgia, and Arizona. This inquiry underscores the complexity of applying federal preemption to various state laws and the potential for differing outcomes based on jurisdiction. ([massarbitration.co](https://massarbitration.co/news/roundup-mdl-amicus-preemption-six-states?utm_source=openai))

The first trial to test design defect claims post-Durnell concluded on October 29, 2026, in St. Louis County, Missouri. The jury unanimously found in favor of Monsanto, rejecting the plaintiffs’ assertions that Roundup was defectively designed and that the company was negligent. This verdict represents a significant victory for Monsanto and may influence the trajectory of similar claims moving forward. ([mdlupdate.com](https://mdlupdate.com/mdl/2741-roundup/?utm_source=openai))

Despite this outcome, the broader litigation landscape remains active. As of November 2026, approximately 916 cases are pending in the federal MDL, a decrease from previous months, indicating ongoing settlements and case resolutions. Additionally, a proposed $7.25 billion class settlement in Missouri state court is under review, aiming to address current and future claims related to non-Hodgkin lymphoma allegedly caused by Roundup. The settlement’s approval status remains pending, with a final decision anticipated in the coming months. ([mdlupdate.com](https://mdlupdate.com/mdl/2741-roundup/?utm_source=openai))

The evolving legal landscape suggests that while failure-to-warn claims have been curtailed by the Supreme Court’s ruling, other avenues for litigation, particularly design defect and negligence claims, continue to be explored. The outcomes of these cases will likely hinge on nuanced interpretations of state laws and the interplay between federal preemption and state-level legal standards.